Amgen's Vectibix meets primary endpoint in metastatic colorectal cancer

19 June 2015

A Phase III trial of Vectibix (panitumumab) and best supportive care by USA-based independent biotech firm Amgen (Nasdaq: AMGN) met its primary endpoint.

The trial demonstrated a statistically-significant improvement in overall survival in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer compared to patients treated with best standard of care alone. Vectibix showed statistical significance for all key secondary endpoints including overall survival in patients with wild-type RAS (absence of mutations in exons 2, 3 and 4 of KRAS and NRAS) in metastatic colorectal cancer.

Adverse events in the Vectibix treatment arm were consistent with the drug’s known safety profile.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK